Free Trial

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics logo
$11.61 -0.78 (-6.30%)
As of 02:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Dyne Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
14

Based on 15 Wall Street analysts who have issued ratings for Dyne Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 15 analysts, 1 has given a hold rating, 12 have given a buy rating, and 2 have given a strong buy rating for DYN.

Consensus Price Target

$47.46
308.80% Upside
According to the 15 analysts' twelve-month price targets for Dyne Therapeutics, the average price target is $47.46. The highest price target for DYN is $66.00, while the lowest price target for DYN is $17.00. The average price target represents a forecasted upside of 308.80% from the current price of $11.61.
Get the Latest News and Ratings for DYN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Dyne Therapeutics and its competitors.

Sign Up

DYN Analyst Ratings Over Time

TypeCurrent Forecast
3/25/24 to 3/25/25
1 Month Ago
2/24/24 to 2/23/25
3 Months Ago
12/26/23 to 12/25/24
1 Year Ago
3/26/23 to 3/25/24
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
12 Buy rating(s)
10 Buy rating(s)
10 Buy rating(s)
6 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$47.46$49.91$50.42$37.43
Forecasted Upside308.80% Upside256.24% Upside110.33% Upside43.62% Upside
Consensus Rating
Buy
Buy
Buy
Buy
Remove Ads

DYN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

DYN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Dyne Therapeutics Stock vs. The Competition

TypeDyne TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.07
2.82
2.54
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside296.90% Upside21,715.17% Upside17.16% Upside
News Sentiment Rating
Neutral News

See Recent DYN News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
3/21/2025JPMorgan Chase & Co.
3 of 5 stars
Tessa Romero
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$18.00 ➝ $17.00+39.57%
3/17/2025HC Wainwright
1 of 5 stars
Andrew Fein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00 ➝ $46.00+276.28%
3/17/2025Chardan Capital
1 of 5 stars
Keay Nakae
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00+309.20%
3/12/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kostas Biliouris
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$50.00+315.63%
3/7/2025Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Louise Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$50.00+308.50%
2/28/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Edward Tenthoff
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$53.00 ➝ $48.00+264.46%
1/24/2025Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Debjit Chattopadhyay
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
1/14/2025Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Issi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$45.00 ➝ $45.00+198.21%
12/13/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$46.00+79.62%
12/12/2024Baird R W
Subscribe to MarketBeat All Access for the recommendation accuracy rating
B. Skorney
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
12/12/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Deschner
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
9/3/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$55.00 ➝ $55.00+78.80%
8/16/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$41.00 ➝ $66.00+44.29%
8/14/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$48.00 ➝ $52.00+19.16%
5/20/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$36.00 ➝ $42.00+22.77%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:00 PM ET.


DYN Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Dyne Therapeutics is $47.46, with a high forecast of $66.00 and a low forecast of $17.00.

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dyne Therapeutics in the last year. There is currently 1 hold rating, 12 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DYN shares.

According to analysts, Dyne Therapeutics's stock has a predicted upside of 308.80% based on their 12-month stock forecasts.

Dyne Therapeutics has been rated by research analysts at BMO Capital Markets, Chardan Capital, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Piper Sandler, Royal Bank of Canada, and Scotiabank in the past 90 days.

Analysts like Dyne Therapeutics more than other "medical" companies. The consensus rating for Dyne Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how DYN compares to other companies.


This page (NASDAQ:DYN) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners